A cost–utility analysis of degarelix in the treatment of advanced hormone-dependent prostate cancer in the United Kingdom

2014 ◽  
Vol 17 (4) ◽  
pp. 233-247 ◽  
Author(s):  
Dawn Lee ◽  
Joshua Porter ◽  
Daniel Gladwell ◽  
Nic Brereton ◽  
Sandy K. Nielsen
Keyword(s):  
Prostate Cancer ◽  
United Kingdom ◽  
Cost Utility ◽  
Cost Utility Analysis ◽  
Utility Analysis ◽  
The United Kingdom

Cost–utility analysis of public health interventions

2019 ◽  
pp. 177-203
Author(s):  
Rhiannon T. Edwards ◽  
Eira Winrow
Keyword(s):  
Public Health ◽  
United Kingdom ◽  
Cost Utility ◽  
Cost Utility Analysis ◽  
Health Interventions ◽  
Utility Analysis ◽  
Public Health Interventions ◽  
The United Kingdom ◽  
Related Quality ◽  
Health Related

This chapter builds upon Chapters 2 and 6 by introducing the reader to the history and concepts of health-related quality of life, cost–utility analysis, quality-adjusted life years (QALYs), and payer thresholds. The aim of this chapter is to outline in more depth the role of applied cost–utility analyses in the economic evaluation of public health interventions. The chapter goes on to reproduce a paper by Owen and colleagues at the National Institute for Health and Care Excellence (NICE) in the United Kingdom. This paper shows that many public health interventions often have a cost per QALY considerably lower than the £20,000 payer threshold conventionally used by NICE in the United Kingdom.

Sign in / Sign up

Export Citation Format

Share Document